Plan Group Financial LLC Has $1.38 Million Stake in Pfizer Inc. (NYSE:PFE)

Key Points

• Plan Group Financial LLC increased its stake in Pfizer Inc. by 51.7% in Q1, owning a total of 54,284 shares valued at approximately $1.38 million.
• Pfizer has announced a quarterly dividend of $0.43 per share, resulting in a 7.3% yield and an annualized dividend payout of $1.72.
• Analysts show a range of opinions on Pfizer, with price targets varying from $25 to $33, and a consensus rating of "Moderate Buy."

Plan Group Financial LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 51.7% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 54,284 shares of the biopharmaceutical company's stock after buying an additional 18,495 shares during the quarter. Plan Group Financial LLC's holdings in Pfizer were worth $1,376,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Brighton Jones LLC lifted its stake in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. Round Hill Asset Management boosted its holdings in Pfizer by 8.2% during the 4th quarter. Round Hill Asset Management now owns 152,162 shares of the biopharmaceutical company's stock worth $4,037,000 after acquiring an additional 11,514 shares during the last quarter. Wellspring Financial Advisors LLC boosted its holdings in Pfizer by 49.9% during the 4th quarter. Wellspring Financial Advisors LLC now owns 16,693 shares of the biopharmaceutical company's stock worth $443,000 after acquiring an additional 5,560 shares during the last quarter. Finally, Certior Financial Group LLC purchased a new position in Pfizer during the 4th quarter worth $421,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Up 0.3%

Shares of PFE opened at $23.56 on Tuesday. The firm has a market cap of $133.95 billion, a P/E ratio of 17.07, a P/E/G ratio of 0.85 and a beta of 0.52. The stock has a 50 day simple moving average of $24.37 and a two-hundred day simple moving average of $24.53. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.3%. Pfizer's dividend payout ratio is currently 124.64%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Jefferies Financial Group lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. The Goldman Sachs Group lifted their price objective on Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. HSBC decreased their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Morgan Stanley lifted their price objective on Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 30th. Finally, Berenberg Bank decreased their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, Pfizer presently has an average rating of "Moderate Buy" and a consensus target price of $28.28.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.